<p>Drug firm Bajaj Healthcare on Tuesday announced the launch of its anti-parasitic drug 'Ivejaj', which can be used for the treatment of Covid infections.</p>.<p>The company has received approval from India's drug regulator DCGI to manufacture and market the tablets, it said in a BSE filing.</p>.<p>Bajaj Healthcare said it has successfully developed the active pharmaceutical ingredient and the formulation for Ivermectin through its own in-house R&D team.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>The DCGI has granted permissions to supply 'Ivejaj' in the domestic as well as overseas markets, Bajaj Healthcare said.</p>.<p>Shares of the company rose 2.71 per cent to Rs 603.30 apiece on BSE.</p>
<p>Drug firm Bajaj Healthcare on Tuesday announced the launch of its anti-parasitic drug 'Ivejaj', which can be used for the treatment of Covid infections.</p>.<p>The company has received approval from India's drug regulator DCGI to manufacture and market the tablets, it said in a BSE filing.</p>.<p>Bajaj Healthcare said it has successfully developed the active pharmaceutical ingredient and the formulation for Ivermectin through its own in-house R&D team.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>The DCGI has granted permissions to supply 'Ivejaj' in the domestic as well as overseas markets, Bajaj Healthcare said.</p>.<p>Shares of the company rose 2.71 per cent to Rs 603.30 apiece on BSE.</p>